.png)
Starting Wegovy: does it work straight away?
Does Wegovy work straight away?
One of the most common questions from people starting Wegovy is whether they should expect to feel something straight away. Wegovy begins acting in the body soon after your first injection, but that is not the same as immediate, visible weight loss. Understanding the difference between biological onset and patient-noticeable results is what sets realistic expectations and keeps new starters on track.
Semaglutide, the active ingredient in Wegovy, reaches peak concentration in the bloodstream within one to three days of an injection. However, the starter dose of 0.25mg is designed to help your body adjust gradually, not to deliver maximum appetite suppression or weight loss from day one. For most patients, the earliest noticeable change is a shift in appetite or fullness, not a dramatic drop on the scales.
What ‘working’ actually means in week one on Wegovy
When patients ask whether Wegovy is “working”, they usually mean one of two different things: what is happening inside the body, and what they can actually feel or see. These two things do not happen at the same time.
Wegovy works by mimicking a naturally occurring hormone called GLP-1 (glucagon-like peptide-1). According to NHS guidance on obesity treatment, GLP-1 receptor agonists help reduce appetite, slow the rate at which the stomach empties, and support blood glucose regulation. All of this begins happening at a biological level from your first dose. What patients notice, however, tends to lag behind.
The table below captures that distinction clearly:
The 0.25mg starting dose is deliberately low. As outlined in our Wegovy dosage guide, this starter phase is about helping your body tolerate the medication safely, not about achieving maximum weight loss. Significant appetite suppression and measurable weight loss tend to build as the dose escalates over subsequent months.
When most people start noticing changes
Clinical trial data gives a useful benchmark for what to expect and when, though individual responses do vary.
The pivotal STEP 1 trial published in the New England Journal of Medicine followed nearly 2,000 adults with obesity or overweight over 68 weeks. Participants taking semaglutide 2.4mg alongside lifestyle changes lost an average of around 2% of their body weight by week 4, progressing to approximately 15% by week 68. The longer-term STEP 5 trial confirmed that weight loss continues to build progressively with sustained treatment, with around a third of participants losing 20% or more of their starting weight after two years.
What this means in practical terms for new starters:
Days 1 to 7
Some people notice a subtle reduction in appetite by day 2 or 3. Others notice very little. Any weight change in the first week is likely to reflect fluid shifts rather than fat loss. This is normal and not a sign that treatment is not working.
Weeks 2 to 4
Appetite changes tend to become slightly more consistent as semaglutide builds up in the system. Average weight loss in clinical trials at the four-week mark is around 2% of body weight, though this varies considerably between individuals. Usually in your first month of Wegovy, actual fat loss typically begins after two to three weeks, once the body starts drawing on stored fat for energy.
Months 2 to 5 (dose escalation phase)
This is where most patients begin to see more consistent, noticeable results. As the dose increases from 0.25mg through to 0.5mg, 1mg, 1.7mg and eventually 2.4mg, appetite suppression strengthens and weight loss accelerates. The STEP 1 trial found average weight loss of approximately 6% by week 12 and around 10% by week 20.
The real takeaway: a quiet first week is not a failed treatment. It is the adjustment phase working as intended.
How to know Wegovy has started to work
Weight is not the only signal worth paying attention to in the early weeks. Several non-scale changes can indicate that semaglutide is beginning to have an effect, and recognising them can help patients stay motivated before more visible results appear.
Look out for:
- Feeling full sooner during meals — finishing a smaller portion and not feeling deprived is one of the earliest signs of GLP-1 activity.
- Staying full for longer after eating — reduced gastric emptying means food stays in the stomach longer, which can reduce the urge to snack.
- Less food noise — some patients describe a quietening of constant thoughts about food or cravings, which can appear before any measurable weight change.
- Fewer urges to overeat — eating to a comfortable level rather than feeling driven to finish everything on the plate.
- Reduced interest in high-calorie foods — some patients report that previously appealing foods feel less compelling.
- Mild nausea or digestive changes — while not pleasant, these early side effects are a sign the medication is active in the body. They usually settle as the body adjusts.
What to track instead of just the scales: appetite changes, portion sizes, snacking frequency, and energy levels in the first few weeks. These give a more complete picture of early progress than weight alone.
When to get advice instead of waiting it out
Reassurance has its limits. While a quiet first week is usually normal, there are situations where patients should contact their prescribing pharmacist rather than simply waiting for things to improve.
Speak to your prescribing pharmacist if you experience:
- Severe or persistent nausea, vomiting, or abdominal pain that does not settle.
- Signs of an allergic reaction: swelling, rash, or difficulty breathing.
- Side effects that feel unmanageable or are affecting daily life.
- No change in appetite or weight after several weeks at an escalated dose.
- Any uncertainty about whether to increase your dose or stay at your current level.
A lack of dramatic results in week one alone is not a clinical reason to stop or change treatment. Dose adjustments should only happen with guidance from your prescribing pharmacist. Starting Wegovy with ongoing clinical oversight means you have support to distinguish between normal adjustment and a genuine need to review your treatment.
Is Wegovy worth starting if it does not feel dramatic straight away?
For anyone weighing up whether to start Wegovy, the honest clinical answer is yes, and the gradual ramp-up is part of what makes it safe and sustainable.
The STEP 1 trial showed that patients who stayed on semaglutide 2.4mg for 68 weeks lost an average of 15% of their body weight. That kind of outcome does not come from a dramatic first week. It comes from consistent treatment, dose escalation over time, and the biological process building steadily in the background from the very first injection.
The right question is not “did I feel something on day one?” It is “am I following the programme correctly and staying consistent?” Those two things are what determine long-term results.
References
- Wilding, J.P.H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Garvey, W.T. et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28, 2083-2091. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- NHS (2023). Obesity - Treatment. National Health Service. https://www.nhs.uk/conditions/obesity/treatment/
.png)